Gastrointestinal bioreactor to evaluate ingestible medicines and inform formulation and manufacture

Lead Research Organisation: University of Strathclyde
Department Name: Inst of Pharmacy and Biomedical Sci

Abstract

One of the major factors limiting understanding the complex dynamic environment in the gut, is the technical difficulty of accessing or visualising the GI tract. GIBio provides a mechanism to replicate the dynamic environment of the gut without the costs or variability associated with animal or human studies such that the design, development and manufacture of formulated ingested products will be transformed. GIBio underpins the development of robust products by providing clinical quality data early in development to accelerate the translation of healthcare technologies to patients. This gold standard equipment, the only accessible facility in the UK, will reduce the time and costs associated with the design, development and manufacture of new drug products.

Oral administration is the most common drug delivery route. Absorption of a drug from the gut into the bloodstream involves disintegration of the dosage form, dissolution of the drug, and transport across the gut wall. The efficiency of these processes is determined by highly complex and dynamic interactions between the gastrointestinal tract, the dosage form and the drug. This complex interplay determines drug delivery performance and may cause large interindividual variability, but is poorly understood. The fine tuning of the equipment to reproduce the gut in health and disease will ensure that patient centric products are developed to improve therapeutic outcomes.



Furthermore, GIBio will generate new research opportunities in formulated ingested products from the food, including animal feed industries and in the evaluation of ingested sensors and medical devices.

Publications

10 25 50
 
Description Membership of INFOGEST group 
Organisation AbbVie Inc
Department AbbVie, Germany
Country Germany 
Sector Private 
PI Contribution The infogest network are working collaboratively to develop a ring study for models of digestion We are performing the relevant studies using the GIBio apparatus to provide data and also leading on a publication that will result from this work
Collaborator Contribution The partners are generating parallel data on alternative models of digestion for hte ring study and also contributing towards the final paper
Impact No outputs yet
Start Year 2023
 
Description Membership of INFOGEST group 
Organisation Merck
Country Germany 
Sector Private 
PI Contribution The infogest network are working collaboratively to develop a ring study for models of digestion We are performing the relevant studies using the GIBio apparatus to provide data and also leading on a publication that will result from this work
Collaborator Contribution The partners are generating parallel data on alternative models of digestion for hte ring study and also contributing towards the final paper
Impact No outputs yet
Start Year 2023
 
Description Membership of INFOGEST group 
Organisation National and Kapodistrian University of Athens
Country Greece 
Sector Academic/University 
PI Contribution The infogest network are working collaboratively to develop a ring study for models of digestion We are performing the relevant studies using the GIBio apparatus to provide data and also leading on a publication that will result from this work
Collaborator Contribution The partners are generating parallel data on alternative models of digestion for hte ring study and also contributing towards the final paper
Impact No outputs yet
Start Year 2023
 
Description Membership of INFOGEST group 
Organisation Novartis
Country Global 
Sector Private 
PI Contribution The infogest network are working collaboratively to develop a ring study for models of digestion We are performing the relevant studies using the GIBio apparatus to provide data and also leading on a publication that will result from this work
Collaborator Contribution The partners are generating parallel data on alternative models of digestion for hte ring study and also contributing towards the final paper
Impact No outputs yet
Start Year 2023
 
Description Membership of INFOGEST group 
Organisation University of Copenhagen
Country Denmark 
Sector Academic/University 
PI Contribution The infogest network are working collaboratively to develop a ring study for models of digestion We are performing the relevant studies using the GIBio apparatus to provide data and also leading on a publication that will result from this work
Collaborator Contribution The partners are generating parallel data on alternative models of digestion for hte ring study and also contributing towards the final paper
Impact No outputs yet
Start Year 2023
 
Description Membership of INFOGEST group 
Organisation University of Leuven
Country Belgium 
Sector Academic/University 
PI Contribution The infogest network are working collaboratively to develop a ring study for models of digestion We are performing the relevant studies using the GIBio apparatus to provide data and also leading on a publication that will result from this work
Collaborator Contribution The partners are generating parallel data on alternative models of digestion for hte ring study and also contributing towards the final paper
Impact No outputs yet
Start Year 2023
 
Description Membership of TIM User Group 
Organisation AbbVie Inc
Department AbbVie, Germany
Country Germany 
Sector Private 
PI Contribution We have supported ongoing efforts to write a white paper and also chaired meetings for the wider team
Collaborator Contribution AstraZeneca have hosted Eleanor Jones for additional training at their site for a period of 2 days to further enhance understanding and to drive towards a longer term collaboration Members of the AZ team also spend 2 days at our facility to further support training and use of the equipment
Impact Current outputs are training records but a white paper is imminent
Start Year 2023
 
Description Membership of TIM User Group 
Organisation AstraZeneca
Department Research and Development AstraZeneca
Country United Kingdom 
Sector Private 
PI Contribution We have supported ongoing efforts to write a white paper and also chaired meetings for the wider team
Collaborator Contribution AstraZeneca have hosted Eleanor Jones for additional training at their site for a period of 2 days to further enhance understanding and to drive towards a longer term collaboration Members of the AZ team also spend 2 days at our facility to further support training and use of the equipment
Impact Current outputs are training records but a white paper is imminent
Start Year 2023
 
Description Membership of TIM User Group 
Organisation Boehringer Ingelheim
Country Germany 
Sector Private 
PI Contribution We have supported ongoing efforts to write a white paper and also chaired meetings for the wider team
Collaborator Contribution AstraZeneca have hosted Eleanor Jones for additional training at their site for a period of 2 days to further enhance understanding and to drive towards a longer term collaboration Members of the AZ team also spend 2 days at our facility to further support training and use of the equipment
Impact Current outputs are training records but a white paper is imminent
Start Year 2023
 
Description Membership of TIM User Group 
Organisation GlaxoSmithKline (GSK)
Department Research and Development GSK
Country United Kingdom 
Sector Private 
PI Contribution We have supported ongoing efforts to write a white paper and also chaired meetings for the wider team
Collaborator Contribution AstraZeneca have hosted Eleanor Jones for additional training at their site for a period of 2 days to further enhance understanding and to drive towards a longer term collaboration Members of the AZ team also spend 2 days at our facility to further support training and use of the equipment
Impact Current outputs are training records but a white paper is imminent
Start Year 2023
 
Description Membership of TIM User Group 
Organisation Johnson & Johnson
Department Janssen Pharmaceutica NV
Country Belgium 
Sector Private 
PI Contribution We have supported ongoing efforts to write a white paper and also chaired meetings for the wider team
Collaborator Contribution AstraZeneca have hosted Eleanor Jones for additional training at their site for a period of 2 days to further enhance understanding and to drive towards a longer term collaboration Members of the AZ team also spend 2 days at our facility to further support training and use of the equipment
Impact Current outputs are training records but a white paper is imminent
Start Year 2023
 
Description Membership of TIM User Group 
Organisation Pfizer Global R & D
Country United States 
Sector Private 
PI Contribution We have supported ongoing efforts to write a white paper and also chaired meetings for the wider team
Collaborator Contribution AstraZeneca have hosted Eleanor Jones for additional training at their site for a period of 2 days to further enhance understanding and to drive towards a longer term collaboration Members of the AZ team also spend 2 days at our facility to further support training and use of the equipment
Impact Current outputs are training records but a white paper is imminent
Start Year 2023
 
Description CMAC Open day 2023 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact The CMAC open day welcomed 288 delegates from 68 companies as well as many academics to the event

Following the event there have been follow up activities from Blazemetrics about involvement in a project
Plus we have been approached by academics to use the GIBio facility for their own research.
Year(s) Of Engagement Activity 2023
URL https://cmac.ac.uk/open-days-2023
 
Description SIPBS Biopharmaceutics Group tour of GIBio 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Postgraduate students
Results and Impact The SIPBS Biopharmaceutics group members received an invitation to visit the GIBio facility to see the artificial intestines for the first time. During their visit, TIM-1 and TIM-2 were set up to conduct an experiment showcasing the peristaltic movements and how samples are taken from TIM-1. Eleanor Jones and Hannah Batchelor explained their functions and use to the group, generating much interest in how they replicate the human gastrointestinal system.
Additional members of staff from the Strathclyde Institute of Pharmacy and Biomedical Sciences attended the event to see how the new equipment could benefit their own research.
After the tour, Hannah Batchelor gave a presentation about the role of GIBio in the Continuous Manufacturing and Crystallisation department (CMAC). This was followed by a cake and craft session where attendees produced posters related to gastrointestinal topics for the GIBio Facility.
Year(s) Of Engagement Activity 2023